Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease - Falkevall, Annelie; Mehlem, Annika; Palombo, Isolde; Heller Sahlgren, Benjamin; Ebarasi, Lwaki; He, Liqun; Ytterberg, A. Jimmy; Olauson, Hannes; Axelsson, Jonas; Sundelin, Birgitta; Patrakka, Jaakko; Scotney, Pierre; et al. (Cell metabolism, 2017)
Keywords: Adult; Aged; albuminuria; Albuminuria - complications; Albuminuria - metabolism; Albuminuria - pathology; Animals; Antibodies, Neutralizing - administration & dosage; Antibodies, Neutralizing - pharmacology; Diabetes Mellitus, Experimental - complications; Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Experimental - pathology; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 1 - metabolism; Diabetes Mellitus, Type 1 - pathology; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - metabolism; Diabetes Mellitus, Type 2 - pathology; diabetic kidney disease; Diabetic Nephropathies - metabolism; Diabetic Nephropathies - pathology; Diabetic Nephropathies - prevention & control; Disease Models, Animal; Disease Progression; Dyslipidemias - complications; Dyslipidemias - metabolism; Dyslipidemias - pathology; endothelial fatty acid transport; Fatty Acid Transport Proteins - metabolism; Female; Gene Deletion; Humans; Insulin - pharmacology; insulin signaling; Kidney - drug effects; Kidney - metabolism; Kidney - pathology; Kidney - physiopathology; Lipids - toxicity; lipotoxicity; Male; Mice, Inbred C57BL; Middle Aged; podocytes; Podocytes - drug effects; Podocytes - metabolism; Podocytes - pathology; renal steatosis; Signal Transduction - drug effects; Up-Regulation - drug effects; vascular endothelial growth factor B; Vascular Endothelial Growth Factor B - metabolism; Young Adult; diabetic kidney disease; albuminuria; insulin signaling; podocytes; lipotoxicity; endothelial fatty acid transport; vascular endothelial growth factor B; renal steatosis